The rise of early highly effective multiple sclerosis treatment in Germany

Real-world data from Germany shows a significant shift in MS treatment strategies—more patients are now starting on early, high-efficacy therapies instead of following the traditional treat-to-target approach. This transition highlights a move towards personalized care that could lead to better long-term outcomes.

By Steffeni Papukchieva, Ann-Sophie Stratil, Maria Kahn, Nils-Henning Neß, Maike Hollnagel Schmitz, Vivien Gerencser, Julia Rustemeier,  Markus Eberl, Benjamin Friedrich, and Tjalf Ziemssen (2024). Shifting from treat-to-target to the early highly effective treatment approach in patients with multiple sclerosis - real-world evidence from Germany. Sage Journal, Therapeutic Advances in Neurological DisordersVolume 17, 2024